MESO
Mesoblast Ltd
$15.44
+0.61 (+4.11%)
At close · Jul 10
Market Cap
$2.00B
Shares
129,282,554
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.44
Open$15.48
Day$15.24–15.73
52W$10.73–21.50
Avg vol 30d203K
Short int3.1M · 2.4% float · 14.9d
Short vol57%
Last earningsDec 31, 2025
DataJan 2020–Jul 2026
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
+5%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
44%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−13%
trailing
YTD return
−14%
this year
Relative strength
−22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $16 — 200d above 50d
Institutional flow
Distributing
2 of 69 funds reported for Jun 30 · net -2.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.40% of float · ▼ -0.2% MoM · 14.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — mid 2-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
4.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
Ryoncil net revenues
· full year 2026
Initiated
$110M – $120M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−5%
Neutral
Price vs 50-day avg
+5%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
44%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $15 › 200d $16 — 200d above 50d
Institutional flow
Distributing
2 of 69 funds reported for Jun 30 · net -2.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.40% of float · ▼ -0.2% MoM · 14.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $11
Now $15 · 44%
52-wk high $22
vs 200-day avg -5%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MESO
this stock
Mesoblast Ltd
|
$2.00B | -14.4% | — | — | 2.4% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MESO | +7.4% | +11.9% | -12.9% | +14.1% | -14.4% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +6.0% | +7.8% | -22.0% | +13.0% | -25.1% |